 truly effective. There have been a lot of drugs that target amyloid proteins that have failed. And so there's been a lot of debate, but still we see this new treatment coming on the market. It did show that it helped slow cognitive decline in trials, but there's a lot of debate about whether that slowing is truly meaningful for patients.